- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Small cell lung cancer (SCLC)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 901.8KB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 294.0KB)
Lurbinectedin – November 2025
Lurbinectedin: Powder for I.V. infusion 2 mg; Zepzelca® - November 2025
Last updated
5 November 2025